Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Treasury Shares (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Treasury Shares data on record, last reported at $724793.0 in Q4 2025.

  • For Q4 2025, Treasury Shares fell 62.16% year-over-year to $724793.0; the TTM value through Dec 2025 reached $724793.0, down 62.16%, while the annual FY2025 figure was $724793.0, 62.16% down from the prior year.
  • Treasury Shares reached $724793.0 in Q4 2025 per TARS's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.0 million in Q1 2024 and bottomed at $17251.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $1.3 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: soared 3095.51% in 2022, then tumbled 65.05% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $17251.0 in 2021, then skyrocketed by 3095.51% to $551258.0 in 2022, then soared by 209.97% to $1.7 million in 2023, then rose by 12.09% to $1.9 million in 2024, then crashed by 62.16% to $724793.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $724793.0 in Q4 2025, $1.7 million in Q3 2025, and $692623.0 in Q2 2025.